acyl-CoA synthetase short chain family member 2Genealiases: ACAS2 · ACECS · ACS · ACSA · AceCS1 · dJ1161H23.1
Q-omics provides the consensus-scored ACSS2 profile across patient tissues and cancer cell-line models. ACSS2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ACSS2 is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, ACSS2 protein abundance shows 26,122 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, and LUAD as cancer lineages where ACSS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACSS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACSS2 survival associations across molecular data types. ACSS2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACSS2 RNA expression–survival associations across cancer types. High ACSS2 expression shows unfavorable associations in ACC, KICH, LGG and GBM, but favorable associations in KIRP and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for ACSS2 RNA expression.
This table summarizes ACSS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ACSS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACSS2 shows lower tumor expression in LUAD, BRCA, LUSC, COAD, THCA and KICH. The LUAD box plot shows higher ACSS2 RNA expression in normal versus tumor tissue (log2 FC = −1.438, t-test p < 0.001).
This table shows molecular features associated with ACSS2 in patient tissues and cancer cell lines. In patient samples, ACSS2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ACSS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
